| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BEIJING, May 29 - Zheng Xiaoyu, former director of China's State Food and Drug Administration (SFDA), was sentenced to death by a Beijing court Tuesday morning.
Zheng, 63, was convicted of taking bribes1 and dereliction of duty, according to the first instance hearing of the Beijing Municipal No. 1 Intermediate People's Court. He received the death penalty on the graft2 charge and 7 years in imprisonment3 for the charge of dereliction of duty. All Zheng's personal property was confiscated4 and he was deprived of his political rights for life. The death sentence was appropriate, according to the court, given the "huge bribes involved and the great damage inflicted5 on the country and the public by Zheng's dereliction of duty". The bribes taken by Zheng, including cash and gifts, were worth more than 6.49 million yuan (about 850,000 U.S. dollars), according to the court. The bribes were given either directly or through his wife and son. The court said Zheng "sought benefits" for eight pharmaceutical6 companies by approving their drugs and medical devices during his tenure7 as China's chief drug and food official from June 1997 to December 2006. "(Zheng's acts) greatly undermined the uprightness of an official post and the efficiency of China's drug monitoring and supervision8, endangered public life and health and had a very negative social impact," the court said. Zheng violated reporting rules and decision-making processes when approving medicines from 2001 to 2003. He failed to make careful arrangements for the supervision of medicine production, which is of critical importance to people's lives, said the court. The consequences of Zheng's dereliction of duty have proved extremely serious. Six types of medicine approved by the administration during that period were fake medicines. Some pharmaceutical companies used false documents to apply for approvals, the court said. It is not yet known whether Zheng will appeal. Zheng, born in December 1944, joined the Communist Party of China in November 1979. He majored in biology at Fudan University in Shanghai. He was the head of the State Pharmaceutical Administration from 1994 to 1998, and head of the State Drug Administration from 1998 to 2003. He was appointed director of the SFDA in May 2003 after it was formed. Zheng retired9 in 2005. He first came under investigation10 by the Communist Party of China's Central Commission for Discipline Inspection11 in December 2006 and was expelled from the Communist Party in March 2007. An official from the CPC Central Commission for Discipline Inspection said: "Zheng's case highlights weaknesses and loopholes in the legal system, the abuse of administrative12 power, a lack of supervision, and weak anti-corruption14 attitudes among officials." Leaders of key departments should rotate positions at fixed15 intervals16 to avoid corruption, the official added. Shao Daosheng, a researcher with the Chinese Academy of Social Sciences, said China's pharmaceutical industry has become a focus of public dissatisfaction for producing fake and substandard medicines and widely using bribery17 to sell their drugs to hospitals. "Commercial bribery is widespread in the pharmaceutical industry, as indecent manufacturers buy licenses18 from corrupt13 regulators," Shao said.
点击  收听单词发音
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TAG标签：
- 发表评论
-
- 最新评论 进入详细评论页>>
